Androgen biosynthesis in castration-resistant prostate cancer

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages

  Penning, Trevor M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Androgen receptor; Androgen receptor antagonists; Enzyme inhibitors; Intratumoral androgen biosynthesis

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 5ALPHA OXIDOREDUCTASE 1; ABIRATERONE; ANDROSTANOLONE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 17; CYTOCHROME P450 17A1; CYTOCHROME P450 17ALPHA HYDROXYLASE; DEOXYCORTICOSTERONE; ENZALUTAMIDE; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 2; STEROID 5ALPHA REDUCTASE 3; STERYL SULFATASE; TESTOSTERONE; TRANSFERASE; UNCLASSIFIED DRUG; URIDINE GLUCURONSYL TRANSFERASE; ENZYME INHIBITOR;

ANDROGEN SYNTHESIS; CANCER CELL; CANCER GROWTH; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; DRUG USE; GENE AMPLIFICATION; HUMAN; MALE; PROTEIN EXPRESSION; REPORTER GENE; REVIEW; SOMATIC MUTATION; STEROID HYDROXYLATION; TESTOSTERONE SYNTHESIS; UPREGULATION; METABOLISM; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

DIHYDROTESTOSTERONE; ENZYME INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TESTOSTERONE;

EID: 84905968578     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0109     Document Type: Review

References (98)

1. Abbott D, Einser JR, Bird IM, Raffrety SW, Moore WR & Schotzinger RJ 2012 Plasma steroid concentrations in male rhesus monkeys following treatment with the P450c17 (CYP) inhibitors VT-464 and abiraterone acetate. A comparison to human 17,20-lyase (lyase) and combined lyase/17α-hydroxylase (hydroxylase) deficiencies. Endocrine Reviews 33 SAT-256.
2. Adamski J, Normand T, Leenders F, Monte D, Begue A, Stehelin D, Jungblut PW & de Launoit Y 1995 Molecular cloning of a novel widely expressed human 80 kDa 17 β-hydroxysteroid dehydrogenase IV. Biochemical Journal 311 437-443.
3. Adeniji A, Twenter BM, Byrns MC, Jin Y, Chen M, Winkler JD & Penning TM 2012 Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl- aminobenzoates and their structure-activity relationships. Journal of Medicinal Chemistry 55 2311-2323. (doi:10.1021/jm201547v)
4. Andersson S, Geissler WM, Patel S & Wu L 1995 The molecular biology of androgenic 17β-hydroxysteroid dehydrogenases. Journal of Steroid Biochemistry and Molecular Biology 53 37-39. (doi:10.1016/0960- 0760(95)00039-3)
5. Andriole G, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ et al. 2010 REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. New England Journal of Medicine 362 1192-1202. (doi:10.1056/ NEJMoa0908127)
6. Astellas Pharmaceuticals J 2013 Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients. Clinical Trials.gov NCT013522082013 http://clinicaltrials.gov/show/NCT013522082013.
7. Attard G, Reid AH, Olmos D & de Bono JS 2009 Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Research 69 4937-4940. (doi:10.1158/0008-5472. CAN-08-4531)
8. Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W et al. 2012 Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. Journal of Clinical Endocrinology and Metabolism 97 507-516. (doi:10.1210/jc.2011-2189)
9. Auchus RJ 2004 The backdoor pathway to dihydrotestosterone. Trends in Endocrinology and Metabolism 15 432-438. (doi:10.1016/j.tem.2004. 09.004)
10. Auchus RJ & Miller WL 2012 Defects in androgen biosynthesis causing 46, XY disorders of sexual development. Seminars in Reproductive Medicine 30 417-426. (doi:10.1055/s-0032-1324726)
11. Bartsch G, Rittmaster RS & Klocker H 2002 Dihydrotestosterone and the concept of 5a-reductase inhibition in human benign prostatic hyperplasia. World Journal of Urology 19 413-425. (doi:10.1007/s00345-002-0248-5)
12. Bauman DR, Steckelbroeck S, Peehl DM & Penning TM 2006α Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology 147 5806-5816. (doi:10.1210/en.2006-0627)
13. Bauman D, Steckelbroeck S, Williams MV, Peehl DM & Penning TM 2006b Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-andostane-3α,17β-diol to 5α-dihydrotestosterone. A potential therapeutic target for androgen dependent disease. Molecular Endocrinology 20 444-458. (doi:10.1210/ me.2005-0287)
14. Bruno R, Gover TD, Burger AM, Brodie AM & Njar VC 2008 17α-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Molecular Cancer Therapeutics 7 2828-2836. (doi:10.1158/1535-7163.MCT-08-0336)
15. Bull H, Garcia-Carlo M, Andersson S, Baginsky WF, Chan K, Ellsworth DE, Miller RR, Stearns RA, Bakshi RK, Rasmusson GH et al. 1996 Mechanism-based inhibition of human steroid 5α-reductase by finasteride: enzyme catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. Journal of the American Chemical Society 118 2359-2365. (doi:10.1021/ja953069t)
16. Byrns M, Jin Y & Penning TM 2011 Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. Journal of Steroid Biochemistry and Molecular Biology 125 95-104. (doi:10.1016/j.jsbmb.2010.11.004)
17. Byrns M, Mindnich R, Duan L & Penning TM 2012 Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride. Journal of Steroid Biochemistry and Molecular Biology 130 7-15. (doi:10.1016/j.jsbmb.2011.12.012)
18. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H et al. 2011 Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Research 71 6503-6513. (doi:10.1158/0008-5472.CAN-11-0532)
19. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, Lehle L, Hombauer H, Adamowicz M, Swiezewska E et al. 2010 SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 142 203-217. (doi:10.1016/ j.cell.2010.06.001)
20. Carstensen JF, Tesdorpf JG, Kaufmann M, Markus MM, Husen B, Leenders F, Jakob F, de Launoit Y & Adamski J 1996 Characterization of 17 β-hydroxysteroid dehydrogenase IV. Journal of Endocrinology 150 (Suppl) S3-12. (doi:10.1677/joe.0.150S003)
21. Castagnetta LA, Carruba G, Traina A, Granata OM, Markus M, Pavone-Macaluso M, Blomquist CH & Adamski J 1997 Expression of different 17β-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells. Endocrinology 138 4876-4882. (doi:10.1210/endo.138.11. 5497)
22. Chang K-H, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ & Sharifi N 2011 Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. PNAS 108 13728-13733. (doi:10.1073/pnas. 1107898108)
23. Chang K-H, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson R, Kapur P, Guo X et al. 2013 A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154 1074-1084. (doi:10.1016/j.cell. 2013.07.029)
24. Chen M, Adeniji AO, Twenter BM, Winkler JD, Christianson DW & Penning TM 2012 Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. Bioorganic and Medicinal Chemistry Letters 22 3492-3497. (doi:10.1016/j.bmcl.2012.03.085)
25. Chung BC, Picado-Leonard J, Haniu M, Bienkowski M, Hall PF, Shively JE & Miller WL 1987 Cytochrome P450c17 (steroid 17 α-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. PNAS 84 407-411. (doi:10.1073/ pnas.84.2.407)
26. Day J, Tutill HJ, Foster PA, Bailey HV, Heaton WB, Sharland CM, Vicker N, Potter BV, Purohit A & Reed MJ 2009 Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β- hydroxysteroid dehydrogenase type 3. Molecular and Cellular Endocrinology 301 251-258. (doi:10.1016/j.mce.2008.08.014)
27. DeVore NM & Scott EE 2012 Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 482 116-119. (doi:10.1038/nature10743)
28. Flanagan JU, Yosaatmadja Y, Teague RM, Chai MZ, Turnbull AP & Squire CJ 2012 Crystal structures of three classes of non-steroidal antiinflammatory drugs in complex with aldo-keto reductase 1C3. PLoS ONE 7 e43965. (doi:10.1371/journal.pone.0043965)
29. Fluck C, Meyer-Boni M, Pandey AV, Kempna P, Miller WL, Schoenle EJ & Biason-Lauber A 2011 Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. American Journal of Human Genetics 89 201-218. (doi:10.1016/j.ajhg.2011.06.009)
30. Frye SV 2006 Discovery and clinical development of dutasteride, a potent dual 5a-reductase inhibitor. Current Topics in Medicinal Chemistry 6 405-421. (doi:10.2174/156802606776743101)
31. Fung K-M, Shea-Samara EH, Wong C, Krin R, Jones AM, Bane B, Liu CZ, Yang JT, Pitha JV, Culkin DJ et al. 2006 Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with the androgen receptor in prostate carcinoma. Endocrine-Related Cancer 13 169-180. (doi:10.1677/erc.1. 01048)
32. Geissler WM, Davis DL, Wu L, Bradshaw KD, Patel S, Mendonca BB, Elliston KO, Wilson JD, Russell DW & Andersson S 1994 Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3. Nature Genetics 7 34-39. (doi:10.1038/ng0594-34)
33. Grosse L, Pâquet S, Caron P, Fazli L, Rennie PS, Bélanger A & Barbier O 2013 Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications. Cancer Research 73 6963-6971. (doi:10.1158/0008-5472.CAN-13-1462)
34. Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A, Martini PG, Katzenellenbogen BS, Martini L, Motta M et al. 2005 The androgen derivative 5α-androstane-3β,17β-diol inhibits prostate cancer cell migration through activation of the estrogen receptor β subtype. Cancer Research 65 5445-5453. (doi:10.1158/0008-5472.CAN-04-1941)
35. Guillemette C, Lévesque E, Beaulieu M, Turgeon D, Hum DW & Bélanger A 1997 Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology 138 2998-3005. (doi:10.1210/endo.138.7.5226)
36. Hamid A, Pfeiffer MJ, Verhaegh GW, Schaafsma E, Brandt A, Sweep FC, Sedelaar JP & Schalken JA 2012 Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castrationresistant prostate cancer. Molecular Medicine 18 1449-1455. (doi:10.2119/molmed.2012.00296)
37. Higashi T, Yamauchi A, Shimada K, Koh E, Mizokami A & Namiki M 2005 Determination of prostatic androgens in 10 mg of tissue using liquid chromatography-tandem mass spectrometry with charged derivatization. Analytical and Bioanalytical Chemistry 382 1035-1043. (doi:10.1007/s00216-005-3233-1)
38. Higashi T, Takayama N, Kyutoku M, Shimada K, Koh E & Namiki M 2006 Liquid chromatography-mass spectrometric assay of androstenediol in prostatic tissue: influence of androgen deprivation therapy on its level. Steroids 71 1007-1013. (doi:10.1016/j.steroids.2006.08.003)
39. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, Schröder FH & de Jong FH 2010 Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Research 70 1256-1264. (doi:10.1158/0008-5472.CAN-09-2092)
40. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E et al. 2012 Distinct transcriptional programsmediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Research 72 3457-3462. (doi:10.1158/0008-5472.CAN-11-3892)
41. Huggins CB 1965 Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Cancer Research 25 1163-1167.
42. Huggins CB & Hodges CV 1941 Studies on prostatic cancer 1. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-397.
43. Jin Y & Penning TM 2006 Multiple steps determine the overall rate of the reduction of 5α-dihydrotestosterone catalyzed by human type 3 3α-hydroxysteroid dehydrogenase: implications for the elimination of androgens. Biochemistry 45 13054-13063. (doi:10.1021/bi060591r)
44. Jin Y, Stayrook SE, Albert RH, Palackal NT, Penning TM & Lewis M 2001 Crystal structure of human type III 3α-hydroxysteroid dehydrogenase/bile acid binding protein complexed with NADPC and ursodeoxycholate. Biochemistry 40 10161-10168. (doi:10.1021/bi010919a)
45. Kennealey GT & Furr BJ 1991 Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. Urologic Clinics of North America 18 99-110.
46. Knudsen K & Penning TM 2010 Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology and Metabolism 21 315-324. (doi:10.1016/j.tem.2010.01.002)
47. Labrie F, Simard J, Luu-The V, Pelletier G, Belanger A, Lachance Y, Zhao HF, Labrie C, Breton N, de Launoit Y et al. 1992 Structure and tissue-specific expression of 3 β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues. Journal of Steroid Biochemistry and Molecular Biology 41 421-435. (doi:10.1016/0960- 0760(92)90368-S)
48. 4-isomerase gene and its expression in mammalian cells. Journal of Biological Chemistry 267 3551.
49. Levy MA, Brandt M, Sheedy KM, Dinh JT, Holt DA, Garrison LM, Bergsma DJ & Metcalf BW 1994 Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 α-reductase isoform 2. Journal of Steroid Biochemistry and Molecular Biology 48 197-206. (doi:10.1016/0960-0760(94)90145- 7)
50. Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, Auchus RJ & Sharifi N 2012 Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clinical Cancer Research 18 3571-3579. (doi:10.1158/1078-0432.CCR-12-0908)
51. Liedtke AJ, Adeniji AO, Chen M, Byrns MC, Jin Y, Christianson DW, Marnett LJ & Penning TM 2013 Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. Journal of Medicinal Chemistry 56 2429-2446. (doi:10.1021/jm3017656)
52. Lin H-K, Jez JM, Schlegel BP, Peehl DM, Pachter JA & Penning TM 1997 Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3α/17β-HSD activity and cellular distribution. Molecular Endocrinology 11 1971-1984. (doi:10.1210/mend.11.13.0026)
53. Lin HK, Steckelbroeck S, Fung KM, Jones AN & Penning TM 2004 Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 69 795-801. (doi:10.1016/j.steroids.2004.09.014)
54. Loriot Y, Fizazi K, Jones RJ, Van den Brande J, Molife RL, Omlin A, James ND, Baskin-Bey E, Heeringa M, Baron B et al. 2014 Safety, tolerability and anti-tumor activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Investigational New Drugs (In Press). (doi:10.1007/s10637-014-0101-x)
55. 2 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Research 64 1802-1810. (doi:10.1158/0008-5472.CAN-03-2847)
56. Luu The V, Lachance Y, Labrie C, Leblanc G, Thomas JL, Strickler RC & Labrie F 1989 Full length cDNA structure and deduced amino acid sequence of human 3 β-hydroxy-5-ene steroid dehydrogenase. Molecular Endocrinology 3 1310-1312. (doi:10.1210/mend-3-8-1310)
57. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL & Scher HI 2012 Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Research 72 6142-6152. (doi:10.1158/0008-5472.CAN-12-1335)
58. Mohler JL, Titus MA & Wilson EM 2011 Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clinical Cancer Research 17 5844-5849. (doi:10.1158/1078-0432.CCR-11-0644)
59. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higian CS, True LD & Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 68 4447-4454. (doi:10.1158/0008-5472.CAN-08-0249)
60. Mostaghel EA, March BT, Plymate SR, Vessella RL, Balk S, Mastsumoto AM, Nelson PS & Montgomery RB 2011 Resistance to CYP17A1 inhibition with abiraterone in castrate-resistance prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical Cancer Research 17 5913-5925. (doi:10.1158/1078-0432.CCR-11-0728)
61. Nadeau G, Bellemare J, Audet-Walsh É, Flageole C, Huang SP, Bao BY, Douville P, Caron P, Fradet Y, Lacombe L et al. 2011 Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. Journal of Clinical Endocrinology and Metabolism 96 1550-1557. (doi:10.1210/jc.2011-1049)
62. Nakajin S & Hall PF 1981 Microsomal cytochrome P-450 from neonatal pig testis. Purification and properties of a C21 steroid side-chain cleavage system (17 α-hydroxylase-C17,20 lyase). Journal of Biological Chemistry 256 3871-3876.
63. Nakajin S, Shively JE, Yuan PM & Hall PF 1981 Microsomal cytochrome P-450 from neonatal pig testis: two enzymatic activities (17α-hydroxylase and c17,20-lyase) associated with one protein. Biochemistry 20 4037-4042. (doi:10.1021/bi00517a014)
64. Njar VC & Brodie AM 1999 Inhibitors of 17α-hydroxylase/17,20- lyase (CYP17): potential agents for the treatment of prostate cancer. Current Pharmaceutical Design 5 163-180. (Pubitemid 29159609)
65. Penning TM, Burczynski ME, Jez JM, Hung C-F, Lin H-K, Ma H, Moore M, Palackal N & Ratnam K 2000 Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochemical Journal 351 67-77. (doi:10.1042/0264-6021:3510067)
66. Pfeiffer MJ, Smit FP, Sedelaar JP & Schalken JA 2011 Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Molecular Medicine 17 657-664. (doi:10.2119/molmed.2010.00143)
67. Purohit A, Williams GJ, Howarth NM, Potter BV & Reed MJ 1995 Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate. Biochemistry 34 11508-11514. (doi:10.1021/ bi00036a025)
68. Purohit A, Woo LW, Singh A, Winterborn CJ, Potter BV & Reed MJ 1996 In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor. Cancer Research 56 4950-4955. (Pubitemid 26374434)
69. 4-isomerase in human adrenals and gonads. Molecular Endocrinology 5 1147-1157. (doi:10.1210/mend-5-8- 1147)
70. Rheaume E, Simard J, Morel Y, Mebarki F, Zachmann M, Forest MG, New MI & Labrie F 1992 Congenital adrenal hyperplasia due to point mutations in the type II 3 β-hydroxysteroid dehydrogenase gene. Nature Genetics 1 239-245. (doi:10.1038/ng0792-239)
71. Rheaume E, Sanchez R, Simard J, Chang YT, Wang J, Pang S & Labrie F 1994 Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 β-hydroxysteroid dehydrogenase deficiency. Journal of Clinical Endocrinology and Metabolism 79 1012-1018. (doi:10.1210/jcem.79.4.7962268)
72. Rizner TL & Penning TM 2013 Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids 79 49-63. (doi:10.1016/j.steroids.2013.10.012)
73. Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR & Penning TM 2003 Human type 3 3α-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 144 2922-2932. (doi:10.1210/en.2002-0032)
74. Russell DW & Wilson JD 1994 Steroid 5α-reductase: two genes/two enzymes. Annual Review of Biochemistry 63 25-61. (doi:10.1146/ annurev.bi.63.070194.000325)
75. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J et al. 2010 Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375 1437-1446. (doi:10.1016/S0140-6736(10)60172-9)
76. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al. 2012 Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 367 1187-1197. (doi:10.1056/NEJMoa1207506)
77. Shapiro LJ 1979 Steroid sulfatase deficiency and X-linked ichthyosis. Clinical Biochemistry 12 205. (doi:10.1016/S0009-9120(79)80096-X)
78. Shapiro LJ 1985 Steroid sulfatase deficiency and the genetics of the short arm of the human X chromosome. Advances in Human Genetics 14 331-381. (doi:10.1007/978-1-4615-9400-0-5)
79. Sharifi R, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB & Stein B 1996 Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clinical Therapeutics 18 647-657. (doi:10.1016/S0149-2918(96)80215-3)
80. Shaw G, Fenelon J, Sichlau M, Auchus RJ, Wilson JD & Renfree MB 2006 Role of the alternate pathway of dihydrotestosterone formation in virilization of the Wolffian ducts of the tammar wallaby, Macropus eugenii. Endocrinology 147 2368-2373. (doi:10.1210/en.2005-1251)
81. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG & Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 66 2815-2825. (doi:10.1158/0008-5472.CAN-05-4000)
82. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B & Penning TM 2004 Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. Journal of Biological Chemistry 279 10784-10795. (doi:10.1074/ jbc.M313308200)
83. Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P, Lin D, Taplin ME, Balk S, Ellis W et al. 2013 Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. Journal of Steroid Biochemistry and Molecular Biology 138C 281-289. (doi:10.1016/j.jsbmb.2013.06. 014)
84. Taplin M-E, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD et al. 2014 Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. Journal of Clinical Oncology [in press].
85. Thomas JL, Mason JI, Brandt S, Spencer BR Jr & Norris W 2002a Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3β-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. Journal of Biological Chemistry 277 42795-42801. (doi:10.1074/jbc.M208537200)
86. Thomas JL, Mason JI, Brandt S & Norris W 2002b Differences in substrate and inhibitor kinetics of human type 1 and type 2 3β- hydroxysteroid dehydrogenase are explained by the type 1 mutant, H156Y. Endocrine Research 28 471-475. (doi:10.1081/ERC-120016825)
87. Thomas JL, Mack VL, Glow JA, Moshkelani D, Terrell JR & Bucholtz KM 2008 Structure/function of the inhibition of human 3β-hydroxysteroid dehydrogenase type 1 and type 2 by trilostane. Journal of Steroid Biochemistry and Molecular Biology 111 66-73. (doi:10.1016/j.jsbmb.2008.04.007)
88. Thompson I, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM et al. 2003 The influence of finasteride on the development of prostate cancer. New England Journal of Medicine 349 215-224. (doi:10.1056/NEJMoa030660)
89. Titus MA, Li Y, Kozyreva OG, Maher V, Godoy A, Smith GJ & Mohler JL 2014 5a-reductase type 3 enzyme in benign and malignant prostate. Prostate 74 235-249. (doi:10.1002/pros.22745)
90. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al. 2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 787-790. (doi:10.1126/science.1168175)
91. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y & Nakagawa H 2008 Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Science 99 81-86. (doi:10.1111/j.1349-7006.2007.00656.x)
92. U.S. Food and Drug Administration 2011 FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. (http://www.fda.gov/drugs/ drugsafety/ucm258314.htm)
93. Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC & Brodie AM 2008 Androgen receptor inactivation contributes to antitumor efficacy of 17α- hydroxylase/17, 20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5, 16-diene in prostate cancer. Molecular Cancer Therapeutics 7 2348-2357. (doi:10.1158/1535- 7163.MCT-08-0230)
94. Vicker N, Sharland CM, Heaton WB, Gonzalez AM, Bailey HV, Smith A, Springall JS, Day JM, Tutill HJ, Reed MJ et al. 2009 The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors. Molecular and Cellular Endocrinology 301 259-265. (doi:10.1016/ j.mce.2008.08.005)
95. Watanabe K, Kakefuda A, Yasuda M, Enjo K, Kikuchi A, Furutani T, Naritomi Y, Otsuka Y, Okada M & Ohta M 2013 Discovery of 2-methyl- 1-{1-[(5-methyl-1 H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor. Bioorganic and Medicinal Chemistry 21 5261-5270. (doi:10.1016/j.bmc.2013.06.025)
96. Wilson JD, Auchus RJ, Leihy MW, Guryev OL, Estabrook RW, Osborn SM, Shaw G & Renfree MB 2003 5α-androstane-3α,17β-diol is formed in tammar wallaby pouch young testes by a pathway involving 5α-pregnane- 3α,17α-diol-20-one as a key intermediate. Endocrinology 144 575-580. (doi:10.1210/en.2002-220721)
97. Yen PH, Allen E, Marsh B, Mohandas T, Wang N, Taggart RT & Shapiro LJ 1987 Cloning and expression of steroid sulfatase cDNA and the frequent occurrence of deletions in STS deficiency: implications for X-Y interchange. Cell 49 443-454. (doi:10.1016/0092-8674(87) 90447-8)
98. Yepuru M, Wu Z, Kyulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT & Narayanan R 2013 Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clinical Cancer Research 19 5613-5625. (doi:10.1158/1078-0432.CCR-13-1151)